10x Genomics, Inc. (TXG) Key Metrics
TXG valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $9.10B
- Enterprise value
- $9.38B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 14.8 10-yr median 10.6
- Price / book
- 11.9 10-yr median 8.8
- EV / EBITDA
- 148.5
- Dividend yield
- —
- Beta
- 1.99
TXG key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTXG valuation Price multiples at each fiscal year-end price.
Price / sales+11.8%
3.2
2025 · hover or tap a bar for each year
20172025
Price / book+4.9%
2.6
2025 · hover or tap a bar for each year
20172025
Free cash flow yield+6.7 pts
6.4%
2025 · hover or tap a bar for each year
20172025
TXG returns How much profit the business earns on the capital it uses.
Return on equity+19.4 pts
−5.8%
2025 · hover or tap a bar for each year
20172025
Return on invested capital+15.2 pts
−21.1%
2025 · hover or tap a bar for each year
20172025
Return on assets+14.9 pts
−4.4%
2025 · hover or tap a bar for each year
20172025
Free cash flow margin+21.2 pts
20.2%
2025 · hover or tap a bar for each year
20172025
Asset turnover+1.2%
0.66
2025 · hover or tap a bar for each year
20172025
TXG per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+1.6%
$5.15
2025 · hover or tap a bar for each year
20172025
Earnings per share
−$0.35
2025 · hover or tap a bar for each year
20172025
Free cash flow per share
$1.04
2025 · hover or tap a bar for each year
20172025
Book value per share+8.3%
$6.38
2025 · hover or tap a bar for each year
20172025
Shares outstanding+3.6%
124.7M
2025 · hover or tap a bar for each year
20172025
TXG financial health Debt, liquidity and how easily interest is covered.
Debt / equity+70.3%
0.20
2025 · hover or tap a bar for each year
20172025
Net debt−$54.9M
−$365.7M
2025 · hover or tap a bar for each year
20172025
Current ratio−10.2%
4.46
2025 · hover or tap a bar for each year
20172025
Debt / assets+68.4%
0.15
2025 · hover or tap a bar for each year
20172025
TXG efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−12 days
48 days
2025 · hover or tap a bar for each year
20172025
Days of inventory−18 days
128 days
2025 · hover or tap a bar for each year
20172025
Days payables outstanding−3 days
24 days
2025 · hover or tap a bar for each year
20172025
Cash conversion cycle−27 days
153 days
2025 · hover or tap a bar for each year
20172025
Capex / revenue−1.1 pts
0.9%
2025 · hover or tap a bar for each year
20172025
TXG valuation history
Fiscal year-endToday9-year median
TXG returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TXG debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TXG cash returned to shareholders
DividendsBuybacksFree cash flow
TXG price vs earnings per share
Share price at year-endEPS (right axis)
TXG key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $2.03B | $1.73B | $6.56B | $4.15B | $16.44B | $14.32B | $5.96B | — | — |
| Enterprise value | $1.67B | $1.42B | $6.26B | $3.81B | $15.93B | $13.72B | $5.57B | — | — |
| Price / sales | 3.2 | 2.8 | 10.6 | 8.0 | 33.5 | 47.9 | 24.2 | — | — |
| Price / book | 2.6 | 2.4 | 8.8 | 5.1 | 20.1 | 19.4 | 14.2 | — | — |
| Price / free cash flow | 15.6 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 15.0 | 259.6 | — | — | — | — | 172.2 | — | — |
| EV / sales | 2.6 | 2.3 | 10.1 | 7.4 | 32.5 | 45.9 | 22.6 | — | — |
| EV / EBITDA | 427.0 | — | — | — | — | — | — | — | — |
| EV / free cash flow | 12.8 | — | — | — | — | — | — | — | — |
| Earnings yield | −2.1% | −10.6% | −3.9% | −4.0% | −0.4% | −3.8% | −0.5% | — | — |
| Free cash flow yield | 6.4% | −0.3% | −1.0% | −4.0% | −0.7% | −1.8% | −0.1% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $16.31 | $14.36 | $55.96 | $36.44 | $148.96 | $141.60 | $76.25 | — | — |
| Per share | |||||||||
| Revenue per share | $5.15 | $5.07 | $5.28 | $4.54 | $4.44 | $2.95 | $3.15 | — | — |
| Earnings per share | −$0.35 | −$1.52 | −$2.18 | −$1.46 | −$0.53 | −$5.37 | −$0.40 | — | — |
| Operating cash flow per share | $1.09 | $0.06 | −$0.13 | −$0.30 | −$0.19 | −$2.15 | $0.44 | — | — |
| Free cash flow per share | $1.04 | −$0.05 | −$0.55 | −$1.45 | −$1.11 | −$2.53 | −$0.10 | — | — |
| Cash per share | $4.20 | $3.27 | $3.32 | $3.78 | $5.32 | $6.56 | $5.43 | — | — |
| Book value per share | $6.38 | $5.90 | $6.32 | $7.08 | $7.41 | $7.31 | $5.37 | — | — |
| Tangible book value per share | $5.85 | $5.73 | $6.14 | $6.84 | $7.14 | $7.09 | $5.37 | — | — |
| Capex per share | $0.05 | $0.10 | $0.42 | $1.16 | $0.92 | $0.38 | $0.55 | — | — |
| Debt per share | $1.26 | $0.69 | $0.81 | $0.84 | $0.74 | $0.62 | $0.38 | — | — |
| Shares outstanding | 124.7M | 120.5M | 117.2M | 113.9M | 110.3M | 101.2M | 78.2M | — | — |
| Change in shares outstanding | +3.6% | +2.8% | +2.9% | +3.2% | +9.1% | +29.4% | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −5.8% | −25.2% | −33.0% | −20.5% | −7.5% | −93.6% | −31.2% | — | — |
| Return on invested capital (ROIC) | −21.1% | −36.3% | −45.6% | −33.9% | −18.6% | −82.2% | — | — | — |
| Return on assets (ROA) | −4.4% | −19.4% | −25.6% | −16.2% | −6.0% | −70.7% | −8.6% | −112.5% | −24.8% |
| Return on tangible assets | −4.5% | −20.3% | −27.0% | −16.6% | −5.9% | −59.8% | −5.2% | −90.8% | −24.8% |
| Free cash flow margin | 20.2% | −0.9% | −10.5% | −32.0% | −25.0% | −85.8% | −3.3% | −56.8% | −20.3% |
| Financial health | |||||||||
| Total debt | $157.7M | $82.6M | $95.4M | $95.2M | $82.0M | $63.0M | $29.7M | $29.7M | $10.6M |
| Cash & short-term investments | $523.4M | $393.4M | $388.7M | $430.0M | $587.4M | $663.6M | $424.2M | $65.1M | $47.9M |
| Net debt | −$365.7M | −$310.8M | −$293.3M | −$334.8M | −$505.5M | −$600.6M | −$394.4M | −$35.4M | −$37.3M |
| Debt / equity | 0.20 | 0.12 | 0.13 | 0.12 | 0.10 | 0.09 | 0.07 | — | — |
| Debt / assets | 0.15 | 0.09 | 0.10 | 0.09 | 0.08 | 0.07 | 0.05 | 0.24 | 0.14 |
| Net debt / EBITDA | −93.55 | — | — | — | — | — | — | — | — |
| Current ratio | 4.46 | 4.97 | 4.69 | 4.85 | 6.77 | 6.56 | 7.63 | 3.28 | 3.08 |
| Quick ratio | 4.09 | 4.26 | 4.11 | 4.23 | 6.23 | 6.30 | 7.38 | 3.02 | 2.86 |
| Interest coverage | — | — | — | -352.8 | -61.1 | -50.7 | -9.4 | -46.0 | -22.7 |
| Working capital | $531.0M | $466.8M | $468.9M | $504.1M | $637.2M | $656.2M | $417.8M | $73.9M | $46.0M |
| Invested capital | $430.7M | $399.3M | $447.7M | $470.9M | $312.1M | $138.4M | $25.6M | −$255.4M | −$149.8M |
| Tangible asset value | $729.5M | $690.0M | $719.9M | $778.4M | $787.7M | $716.7M | $419.7M | −$220.4M | −$112.5M |
| Net current asset value | $439.4M | $375.9M | $371.9M | $411.8M | $546.3M | $584.1M | $295.0M | −$238.1M | −$120.0M |
| Graham net-net per share | $2.95 | $2.43 | $2.45 | $2.86 | $4.35 | $5.21 | $3.47 | — | — |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $80,000 |
| Capex / revenue | 0.9% | 2.0% | 8.0% | 25.5% | 20.6% | 12.8% | 17.4% | 4.6% | 5.3% |
| Capex / operating cash flow | 4.4% | 186.0% | — | — | — | — | 123.5% | — | — |
| Capex / depreciation | 0.14 | 0.28 | 1.14 | 3.99 | 3.58 | 2.02 | 6.05 | 1.72 | 0.87 |
| Stock-based compensation / revenue | 17.0% | 23.0% | 27.0% | 26.5% | 19.6% | 16.3% | 5.4% | 1.8% | 2.3% |
| R&D / revenue | 37.1% | 43.3% | 43.7% | 51.4% | 43.2% | 41.3% | 33.8% | 32.5% | 45.2% |
| SG&A / revenue | 49.2% | 56.4% | 55.5% | 57.8% | 52.5% | 67.7% | 53.2% | 60.1% | 65.7% |
| Efficiency | |||||||||
| Days sales outstanding | 48.4 | 60.6 | 64.6 | 67.0 | 50.8 | 51.7 | 45.6 | 51.7 | 68.5 |
| Days of inventory on hand | 127.9 | 145.8 | 135.4 | 214.7 | 221.5 | 141.2 | 71.3 | 85.4 | 167.2 |
| Days payables outstanding | 23.5 | 26.6 | 32.5 | 59.0 | 54.3 | 55.4 | 65.2 | 90.6 | 188.1 |
| Cash conversion cycle (days) | 152.8 | 179.7 | 167.4 | 222.6 | 217.9 | 137.5 | 51.7 | 46.4 | 47.6 |
| Receivables turnover | 7.55 | 6.03 | 5.65 | 5.45 | 7.19 | 7.07 | 8.00 | 7.06 | 5.33 |
| Payables turnover | 15.52 | 13.70 | 11.22 | 6.18 | 6.72 | 6.59 | 5.59 | 4.03 | 1.94 |
| Inventory turnover | 2.85 | 2.50 | 2.70 | 1.70 | 1.65 | 2.59 | 5.12 | 4.28 | 2.18 |
| Asset turnover | 0.66 | 0.65 | 0.62 | 0.50 | 0.50 | 0.39 | 0.67 | 1.46 | 0.94 |
| Average receivables | $85.2M | $101.3M | $109.5M | $94.7M | $68.2M | $42.3M | $30.7M | $20.7M | $13.3M |
| Average payables | $12.8M | $14.3M | $18.7M | $19.5M | $11.0M | $8.9M | $10.9M | $7.1M | $5.4M |
| Average inventory | $69.7M | $78.4M | $77.7M | $70.8M | $45.0M | $22.6M | $11.9M | $6.7M | $4.8M |
| Intangibles / total assets | 6.4% | 2.2% | 2.2% | 2.7% | 2.9% | 2.4% | 0.1% | 0.3% | 0.0% |
Computed from TXG's annual financial statements (latest annual report filed February 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TXG valuation and financial ratios
10x Genomics earned a return on equity of −5.8% and a return on invested capital of −21.1% in fiscal 2025. It ended the year with $157.7 million of debt and $523.4 million in cash and short-term investments, a net cash position of $365.7 million.
See the TXG income statement, the TXG chart for price history, or the TXG stock overview for the latest quote and news.
TXG key metrics FAQ
What is 10x Genomics's EV/EBITDA?
10x Genomics's enterprise value was 427.0 times EBITDA at the end of fiscal 2025 (enterprise value $1.7 billion, EBITDA $3.9 million); the current EV/EBITDA is 148.5.
What is 10x Genomics's return on equity?
10x Genomics's return on equity (ROE) was −5.8% in fiscal 2025: net income of -$43.5 million on average shareholders' equity of $753.2 million.
What is 10x Genomics's ROIC?
10x Genomics's return on invested capital was −21.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does 10x Genomics have?
10x Genomics had total debt of $157.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.20 and more cash than debt.
What is 10x Genomics's free cash flow yield?
10x Genomics generated $130.1 million of free cash flow in fiscal 2025, a free cash flow yield of 6.4% on its market value at year-end ($2.0 billion).
What is 10x Genomics's current ratio?
10x Genomics's current ratio was 4.46 at the end of fiscal 2025: current assets were 4.46 times current liabilities.